BioCatalyst

frexalimab, brivekimig, rilzabrutinib — catalyst calendar

1 verified catalyst event(s) referencing frexalimab, brivekimig, rilzabrutinib, each linked to its official source. Verified as of 2026-09-20.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12-23
in 3mo
ESTIMATED
 READOUT
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzab
Phase 2 · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
 SNY Sanofi frexalimab, brivekimig, rilzabrutinib ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.